Skip to content
BioMarin
-
BioMarin completes US$4.8B acquisition of Amicus Therapeutics to expand rare disease portfolio
The acquisition brings Amicus Therapeutics fully under BioMarin’s global operations, integrating its late-stage and commercial-stage rare disease assets into BioMarin’s established infrastructure.